Lantern Pharma Inc.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc.는 인도에서 항암제 발굴 및 개발에 주력하고 있습니다. 주요 파이프라인으로는 비흡연 비소세포폐암 선암 환자를 위한 병용 요법으로 임상 2상 시험 중인 LP-300; 진행성 또는 전이성 고형암(췌장암, 유방암, 방광암, 폐암 등), 절제 불가능하거나 재발성 교모세포종(GBM) 및 기타 중추신경계(CNS) 암 치료를 위해 임상 1a상 시험 중인 LP-184; 그리고 맨틀 세포 림프종 및 이중 발현 림프종을 포함한 비호지킨 림프종 치료를 위해